The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.625
Bid: 8.50
Ask: 8.75
Change: -0.125 (-1.43%)
Spread: 0.25 (2.941%)
Open: 8.75
High: 8.75
Low: 8.625
Prev. Close: 8.75
IXI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

13 Jan 2017 15:25

RNS Number : 1709U
IXICO plc
13 January 2017
 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

IXICO plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

x

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify): New issue of shares

x

3. Full name of person(s) subject to thenotification obligation: iii

IP Group plc

4. Full name of shareholder(s)  (if different from 3.):iv

See section 9

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

09 January 2017

6. Date on which issuer notified:

13 January 2017

7. Threshold(s) that is/are crossed orreached: vi, vii

Direct interests: 21% reached

Indirect interests: Unchanged

Combined direct and indirect interests: 24% reached

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

 

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary 1p

6,001,506

6,001,506

5,704,585

5,704,585

809,774

21.08%

2.99%

GB00BCLY7L40

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

6,514,359

24.07%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

Direct interests:

 

IP2IPO Limited: 5,704,585

 

IP2IPO Limited is a 100%-owned subsidiary of IP Group plc.

 

 

Indirect interests:

 

North East Technology Fund - 809,774

 

North East Technology Fund is a limited partnership fund that is managed by Top Technology Ventures Limited, a 100% subsidiary of IP Group plc.

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

Based on 27,063,284 Ordinary Shares in issue

14. Contact name:

Greg Smith

15. Contact telephone number:

0207 444 0050

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLBJMATMBTBBTR
Date   Source Headline
15th Apr 20247:00 amRNSLife Molecular Imaging – Neuraceq Supply Agreement
3rd Apr 20247:00 amRNSImeka Collaboration Agreement
13th Mar 20247:00 amRNSTrading Update
29th Jan 202412:00 pmRNSHolding(s) in Company
25th Jan 20244:00 pmRNSResult of AGM
12th Jan 20249:35 amRNSDirectorate Change
27th Dec 20237:00 amRNSUpdate regarding Nominated Adviser and Broker
15th Dec 20237:00 amRNSChange of Auditor
5th Dec 20237:00 amRNSFinancial Results for year ended 30 September 2023
27th Nov 20237:00 amRNSNotice of Results and Investor Presentation
5th Oct 20237:00 amRNSAppointment of Independent Non-Executive Director
29th Sep 20237:00 amRNSTrading Update
18th Jul 20237:00 amRNSContract Win
14th Jun 20237:00 amRNSContract Win
23rd May 20237:00 amRNSHalf year report
16th May 20237:00 amRNSInvestor Meet Company presentation
10th May 20237:00 amRNSTrading Update
3rd Apr 20238:35 amRNSExtension of Huntington's disease consortium
21st Mar 202312:11 pmRNSHolding(s) in Company
10th Mar 20237:00 amRNSContract Win
7th Feb 20237:00 amRNSTrading Update
31st Jan 20234:35 pmRNSPrice Monitoring Extension
31st Jan 20232:05 pmRNSSecond Price Monitoring Extn
31st Jan 20232:00 pmRNSPrice Monitoring Extension
31st Jan 202311:05 amRNSSecond Price Monitoring Extn
31st Jan 202311:00 amRNSPrice Monitoring Extension
27th Jan 20231:00 pmRNSResult of AGM
3rd Jan 20237:00 amRNSTotal Voting Rights
22nd Dec 202212:18 pmRNSDirector Bed & ISA Dealing
13th Dec 20227:00 amRNSPDMR Exercise of Options
9th Dec 20229:05 amRNSContract Win
8th Dec 20223:34 pmRNSContract Update
7th Dec 20227:00 amRNSFinancial Results for the year ended 30 Sept 2022
21st Nov 20227:00 amRNSNotice of Results and Investor Presentation
25th Oct 20227:00 amRNSTrading Update
21st Sep 202210:35 amRNSHD-IH Consortium
14th Sep 20227:00 amRNSGrant of Share Options
1st Sep 20227:00 amRNSTrading Update and FY2023 Guidance
4th Aug 20227:00 amRNSContract Win
26th Jul 202211:22 amRNSContract Win - Replacement
21st Jul 20227:00 amRNSContract Win
14th Jun 20227:00 amRNSContract Extension
24th May 20227:00 amRNSHalf-year Report and Trading Update
16th May 20227:00 amRNSInvestor Presentation
10th May 20227:00 amRNSConsortium Agreement in Huntington's Disease
25th Apr 20227:00 amRNSTrading Update
21st Apr 20227:00 amRNSNew Contract Win
8th Mar 20227:00 amRNSContract worth circa £800k
14th Feb 20227:00 amRNSLaunch of IXIQ.Ai Deep learning AI-based platform
8th Feb 202212:30 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.